Diisopropylethylamine → N-(5-(3,3-difluoropiperidin-1-yl)-1-(2-((trimethylsilyl)methoxy)ethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
Reaction equation
[F:1][C:2]1([F:22])[CH2:7][CH2:6][CH2:5][N:4]([C:8]2[N:12]([CH2:13][CH2:14][O:15][CH2:16][Si:17]([CH3:20])([CH3:19])[CH3:18])[N:11]=[CH:10][C:9]=2[NH2:21])[CH2:3]1.CCN(C(C)C)C(C)C.[N:32]1[N:36]2[CH:37]=[CH:38][CH:39]=[N:40][C:35]2=[C:34]([C:41](Cl)=[O:42])[CH:33]=1>C1COCC1>[F:22][C:2]1([F:1])[CH2:7][CH2:6][CH2:5][N:4]([C:8]2[N:12]([CH2:13][CH2:14][O:15][CH2:16][Si:17]([CH3:19])([CH3:18])[CH3:20])[N:11]=[CH:10][C:9]=2[NH:21][C:41]([C:34]2[CH:33]=[N:32][N:36]3[CH:37]=[CH:38][CH:39]=[N:40][C:35]=23)=[O:42])[CH2:3]1Participants
Reactant 3
Product 1
Reagents, catalysts & solvents 1
Procedure
To a solution of 5-(3,3-difluoropiperidin-1-yl)-1-(2-((trimethylsilyl)methoxy)ethyl)-1H-pyrazol-4-amine (1.2 g, 3.61 mmol) in 30 mL THF was added DIPEA (1.3 mL, 7.22 mmol) and pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (720 mg, 3.97 mmol) in THF (50 mL) at 0° C. After addition was complete, the mixture was warmed to room temperature, then stirred overnight. The mixture was concentrated in vacuo and the residue was purified by silica gel column chromatogaphy (hexanes:EtOAc=3:1 to 1:1) to afford 1.0 g (60%) of N-(5-(3,3-difluoropiperidin-1-yl)-1-(2-((trimethylsilyl)methoxy)ethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide. LCMS (ESI) m+H=478.2; 1H NMR (400 MHz, CDCl3) δ: 9.49 (s, 1H), 8.87 (dd, 1H), 8.75 (s, 1H), 8.71 (dd, 1H), 7.94 (s, 1H), 7.10 (dd, 1H), 5.40 (s, 2H), 3.67 (m, 6H), 2.06 (s, 2H), 1.93 (m, 2H), 0.95 (m, 2H), 0 (s, 9H).
Workup
- additionAfter addition
- concentrationThe mixture was concentrated in vacuo
- customthe residue was purified by silica gel column chromatogaphy (hexanes:EtOAc=3:1 to 1:1)
Sources & evidence
- ORD record
- ord-8a5dbd67044b4f0c8a6f14ec1f9f61e8
- Source dataset
- uspto-grants-2015_04
- Patent number
- US08999998B2
Reaction notes
Loading…